TEVA Form 144: Proposed sale of 30,000 shares, $753,321 value

Teva Pharmaceutical Industries (TEVA) received a Form 144 notice for a planned sale of up to 30,000 ordinary shares.

Accepted by SEC EDGAR 11/14/2025 - 03:59 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries (TEVA) received a Form 144 notice for a planned sale of up to 30,000 ordinary shares. The filing lists an aggregate market value of $753,321, with an approximate sale date of 11/14/2025. The proposed broker is Citigroup Global Markets Inc., and the shares are listed on the NYSE. The seller reports acquiring the shares on 11/20/2024 via a shares from rollover transaction, with the consideration described as compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares are covered by this Form 144 notice?

The notice covers up to 30,000 ordinary shares.

What is the aggregate market value of the TEVA shares to be sold?

The filing lists an aggregate market value of $753,321.

When is the approximate sale date for the TEVA shares?

The filing states an approximate sale date of 11/14/2025.

Which broker is named for the TEVA share sale?

The broker is Citigroup Global Markets Inc.

On which exchange are the TEVA shares listed for this sale?

The filing names the NYSE.

How and when were the TEVA shares acquired?

The shares were acquired on 11/20/2024 via shares from rollover, with consideration noted as compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001998173
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Fox Christine
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EVP HEAD OF US COMMERCIAL

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	30000	753321.00	1147282512	11/14/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	11/20/2024	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			30000	11/14/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES
Date of Notice	11/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)